Dimitris Poulcharidis

Dr. Dimitris Poulcharidis

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LKLi Kong
Li Kong
DPDimitris Poulcharidis
Dimitris Poulcharidis
GSGregory F. Schneider
Gregory F. Schneider
FCFrederick Campbell
Frederick Campbell
AKAlexander Kros
Alexander Kros
In the treatment of cancer, targeting of anticancer drugs to the tumor microenvironment is highly desirable. Not only does this imply accurate tumor targeting but also minimal drug release en route to the tumor and maximal drug release once there. Here we describe high-loading, “stealth-like” doxorubicin micelles as a pro-drug delivery system, which upon light activation, leads to burst-like doxorbicin release. Through this approach, we show precise spatiotemporal control of doxorubicin delivery to cells in vitro.

24 May 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
DPDimitris Poulcharidis
Dimitris Poulcharidis
KBKimberley Belfor
Kimberley Belfor
AKAlexander Kros
Alexander Kros
SKSander I. van Kasteren
Sander I. van Kasteren
A technically simple and broadly deployable FACS-based assay to determine intercellular exchange of membrane components.

17 September 2021 in Materials
Verified
Journal Article
Open access
PDF file
FTFani Tsitouroudi
Fani Tsitouroudi
VSVasiliki Sarli
Vasiliki Sarli
DPDimitris Poulcharidis
Dimitris Poulcharidis
MPMaria Pitou
Maria Pitou
AKAlexandros Katranidis
Alexandros Katranidis
Theodora Choli-PapadopoulouTheodora Choli-Papadopoulou
Theodora Choli-Papadopoulou
Reversine or 2-(4-morpholinoanilino)-N6-cyclohexyladenine was originally identified as a small organic molecule that induces dedifferentiation of lineage-committed mouse myoblasts, C2C12, and redirects them into lipocytes or osteoblasts under lineage-specific conditions (LISCs). Further, it was proven that this small molecule can induce cell cycle arrest and apoptosis and thus selectively lead cancer cells to cell death. Further studies demonstrated that reversine, and more specifically the C2 position of the purine ring, can tolerate a wide range of substitutions without activity loss. In this study, a piperazine analog of reversine, also known as aza-reversine, and a biotinylated derivative of aza-reversine were synthesized, and their potential medical applications were investigated by transforming the endoderm originates fetal lung cells (MRC-5) into the mesoderm originated osteoblasts and by differentiating mesenchymal cells into osteoblasts. Moreover, the reprogramming capacity of aza-reversine and biotinylated aza-reversine was investigated against MRC-5 cells and mesenchymal cells after the immobilization on PMMA/HEMA polymeric surfaces. The results showed that both aza-reversine and the biofunctionalized, biotinylated analog induced the reprogramming of MRC-5 cells to a more primitive, pluripotent state and can further transform them into osteoblasts under osteogenic culture conditions. These molecules also induced the differentiation of dental and adipose mesenchymal cells to osteoblasts. Thus, the possibility to load a small molecule with useful “information” for delivering that into specific cell targets opens new therapeutic personalized applications.